Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 3/20 | 0.41 |
| ▸ | FNTB | P49356 | 3/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5142634 | 0.99 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1FNTAFNTBARG1 | |
| SCHEMBL5143213 | 0.85 | GAA (0.43) | FNTAFNTBARG1GAAMEN1 | |
| Hydrochloric Acid SCHEMBL5144943 | 0.84 | GAA (0.42) | FNTAFNTBARG1GAAMEN1 | |
| SCHEMBL6648370 | 0.83 | DPP8 (0.44) | L3MBTL3L3MBTL1ARG1ALDH1A1DPP8 | |
| SCHEMBL5981311 | 0.82 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1FNTAFNTBALDH1A1 | |
| Hydrochloric Acid SCHEMBL5891509 | 0.82 | DPP8 (0.43) | L3MBTL3L3MBTL1ARG1ALDH1A1DPP8 | |
| Hydrochloric Acid SCHEMBL5891512 | 0.82 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1ARG1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5142564 | 0.81 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1FNTAFNTBALDH1A1 | |
| SCHEMBL4679523 | 0.80 | DPP4 (0.44) | L3MBTL3L3MBTL1GAAALDH1A1DPP8 | |
| SCHEMBL6600870 | 0.80 | DPP4 (0.44) | L3MBTL3L3MBTL1GAAALDH1A1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297706-B2 | Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070072869-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | WILEY MICHAEL R | 2007-03-29 | — | — | US | disclosed |
| US-7078415-B2 | Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1455787-B1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | LILLY CO ELI (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040249155-A1 | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| EP-1455787-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003049735-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249155-A1 | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders | F2, F11, SERPINC1 | L3MBTL3 2502/4885L3MBTL1 564/4885FNTA 749/4885 |
| US-20070072869-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | F2, F11, F12 | L3MBTL3 1670/4885L3MBTL1 577/4885FNTA 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.